دورية أكاديمية
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy
| العنوان: | Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy |
|---|---|
| المؤلفون: | Nobili S., Checcacci D., Filippelli F., Del Buono S., Mazzocchi V., Mazzei T., Mini E. |
| المساهمون: | Nobili, S., Checcacci, D., Filippelli, F., Del Buono, S., Mazzocchi, V., Mazzei, T., Mini, E. |
| سنة النشر: | 2008 |
| المجموعة: | ARUd'A - Archivio Istituzionale della ricerca dell'università Chieti-Pescara (IRIS) |
| مصطلحات موضوعية: | 5-fluorouracil, Colorectal cancer, Combination chemotherapy, Irinotecan, Oxaliplatin, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocol, Camptothecin, Colorectal Neoplasm, Drug Resistance, Neoplasm, Female, Fluorouracil, Human, Kaplan-Meier Estimate, Leucovorin, Male, Middle Aged, Neoplasm Recurrence, Local, Organoplatinum Compound, Salvage Therapy |
| الوصف: | This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen. Colorectal cancer patients were given bimonthly CPT-11 as a 90-min infusion, followed by OHP (85 mg/m2), FA (200 mg/m2) 2-h infusions and 5-FU (48-h infusion). CPT-11 and 5-FU doses were escalated as reported below. 26 patients were recruited. Fourteen patients had received a prior CPT-11-, 6 patients a prior OHP-based chemotherapy regimen and 6 patients both regimens. Three dose levels were investigated: CPT-11 100, 120 and 140 mg/m2 and 5-FU 1500, 1800 and 2100 mg/m2 in 6, 12 and 8 patients, respectively. All patients were evaluable for toxicity, 24 for antitumor activity. At all dose levels toxicity was acceptable. Grade 4 toxicity occurred in two patients only (neutropenia in one case and stomatitis in another one, 3.8%). Grade 3 toxicities included nausea and vomiting (34.6%), asthenia (26.9%), neurosensory toxicity (15.4%), neutropenia (3.8%) and diarrhea (3.8%). Hematological toxicity was infrequent and generally mild. At the third dose level, a higher, although not significantly different incidence of hematological and neurosensory toxicity (both occurring in 62.5% of cases, all grades) was observed compared to the other two, while nausea and vomiting were significantly less frequent (37.5% vs 100%). Overall, we observed 2 complete responses, 9 partial responses (OR 45.8%), 8 stable disease (33.3%), and 5 disease progression (20.8%). Median overall survival was 18 months and median time-to-progression 5.5 months. This combination showed moderate toxicity and promising antitumor activity in CPT-11 and/or OHP pretreated colorectal cancer patients. The second dose level using CPT-11 at 120 mg/m2 and 5-FU at 1800 mg/m2 is recommended for further phase II studies in this patient population. © E.S.I.F.T. srl - ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/19028627; info:eu-repo/semantics/altIdentifier/wos/WOS:000261111800014; volume:20; issue:5; firstpage:622; lastpage:631; numberofpages:10; journal:JOURNAL OF CHEMOTHERAPY; http://hdl.handle.net/11564/737385Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-57049164995 |
| DOI: | 10.1179/joc.2008.20.5.622 |
| الإتاحة: | https://doi.org/10.1179/joc.2008.20.5.622Test http://hdl.handle.net/11564/737385Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.26C3D650 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1179/joc.2008.20.5.622 |
|---|